ICON

ICON Reports Q4 and Full-Year 2025 Results, Shares Audit Committee Investigation Findings

ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation ICON plc a world-leading clinical research organization, reported its financial results for the fourth quarter and full year 2025, and announced the outcome of its…

Read MoreICON Reports Q4 and Full-Year 2025 Results, Shares Audit Committee Investigation Findings
Secretome

Secretome Therapeutics Secures $30M Series A Led by RA Capital to Advance STM-01 for Duchenne Cardiomyopathy

Secretome Therapeutics Announces $30 Million Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), announced the closing of a $30…

Read MoreSecretome Therapeutics Secures $30M Series A Led by RA Capital to Advance STM-01 for Duchenne Cardiomyopathy
Wolters

Wolters Kluwer and RSNA Sign 10-Year Deal to Expand Global Access to Radiology Research Journals

Wolters Kluwer and Radiological Society of North America Establish 10-Year Agreement to Advance Global Access to Leading Radiology Research Journals Wolters Kluwer Health announced a new 10-year agreement to publish the Radiological Society of North America (RSNA) portfolio of five specialty journals…

Read MoreWolters Kluwer and RSNA Sign 10-Year Deal to Expand Global Access to Radiology Research Journals
Hepta

Hepta Blood Test Surpasses FIB-4, ELF, and FibroScan in Detecting Treatment-Eligible MASH Patients

Hepta’s Blood Test Outperforms FIB-4, ELF, and FibroScan in Identifying Treatment-Eligible MASH Patients Hepta, a liquid biopsy company developing blood tests for chronic disease, announced clinical data showing its blood test more accurately identifies metabolic dysfunction-associated steatohepatitis (MASH) patients eligible…

Read MoreHepta Blood Test Surpasses FIB-4, ELF, and FibroScan in Detecting Treatment-Eligible MASH Patients
Archeus Technologies Doses First Patient in Phase 1 Study of ARC-706 and Companion Diagnostic ARC-166 for Metastatic Cancer

Archeus Technologies Begins Phase 1 Trial of ARC-706 and ARC-166 in Metastatic Cancer Patients

Archeus Technologies Doses First Patient in Phase 1 Study of ARC-706 and Companion Diagnostic ARC-166 for Metastatic Cancer Archeus Technologies, a clinical-stage company advancing a portfolio of differentiated small-molecule radiopharmaceutical therapies (RPTs) to address some of the most difficult-to-treat cancers,…

Read MoreArcheus Technologies Begins Phase 1 Trial of ARC-706 and ARC-166 in Metastatic Cancer Patients
Polar Semiconductor and Nexperia Partner on Power MOSFET Manufacturing to Strengthen Global Supply

Polar Semiconductor and Nexperia Partner to Expand Power MOSFET Manufacturing Capacity

Polar Semiconductor and Nexperia Partner on Power MOSFET Manufacturing to Strengthen Global Supply Polar Semiconductor, LLC and Nexperia B.V. announced a strategic collaboration to manufacture next‑generation power MOSFET devices at Polar Semiconductor’s U.S.‑based wafer foundry. The partnership supports an expanded…

Read MorePolar Semiconductor and Nexperia Partner to Expand Power MOSFET Manufacturing Capacity
Inbolt Launches Vision-Enabled Robot

Inbolt Launches Vision-Enabled Robot Programming to Streamline CAD-to-Factory Production

Inbolt Launches Vision-Enabled Robot Programming, Closing the Loop from CAD to Factory Floor Inbolt, the robot intelligence company that turns digital twins into live robot control, is launching two new capabilities that complete the company’s AI vision model for robot guidance:…

Read MoreInbolt Launches Vision-Enabled Robot Programming to Streamline CAD-to-Factory Production
Turn Therapeutics Inc. a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and

Turn Therapeutics Reports GX-03 Activity in IL-36 Inflammatory Model Study Published in Journal of Dermatological Treatment

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model Turn Therapeutics Inc. a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, announced the publication of…

Read MoreTurn Therapeutics Reports GX-03 Activity in IL-36 Inflammatory Model Study Published in Journal of Dermatological Treatment
Delcath Systems

Delcath Systems Highlights Two ASCO 2026 Trials-in-Progress Abstracts

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts Delcath Systems, Inc. an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May…

Read MoreDelcath Systems Highlights Two ASCO 2026 Trials-in-Progress Abstracts
Octave Bioscience

Octave Bioscience Appoints Zachary Fernandes as VP to Expand Strategic Partnerships

Octave Bioscience Accelerates Precision Neurology Momentum, Appoints Zachary Fernandes as VP of Business Development to Scale Strategic Partnerships Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker-driven solutions for multiple sclerosis, Parkinson’s and other neurodegenerative diseases, today announced…

Read MoreOctave Bioscience Appoints Zachary Fernandes as VP to Expand Strategic Partnerships